WFS1 and metabolic disease: Riluzole, a United States Food & Drug Administration (FDA)‐approved drug for ALS, could alleviate the neural cell death and behavior phenotype of Wfs1 deficient mice.[26] Inhibiting the glutamate release from nerve terminals as the predominant neuroprotective mechanism for riluzole target ALS patients.[66, 67] Comorbidity exists between metabolic disorders and depressive syndrome with unclear mechanisms.